Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

Insider Analysis from Sidley Austin LLP: The Coke/Huiyuan Veto and Its Implication for Life Sciences Companies in China

This article was originally published in PharmAsia News

Executive Summary

By William Fifield, Chen Yang, Katherine Wang and Adrian Emch, Sidley Austin LL

You may also be interested in...



Novartis Tagged With Anti-monopoly Conditions In China For Alcon Acquisition

HONG KONG - China's growing assertiveness in commercial matters is becoming evident in its influence on merger and acquisitions matters and its willingness to impose conditions under its two-year-old anti-monopoly law

Novartis Tagged With Anti-monopoly Conditions In China For Alcon Acquisition

HONG KONG - China's growing assertiveness in commercial matters is becoming evident in its influence on merger and acquisitions matters and its willingness to impose conditions under its two-year-old anti-monopoly law

Emerging Market Outlook: PharmAsia News Earnings Call Roundup

In a new feature, PharmAsia News takes a look at the earnings calls for some of the major pharma companies and what they are saying about Asia Pacific and emerging markets

Table

View full table

Tags:
Latest Headlines

Roche Gets Adjuvant ALK+ Lung Cancer To Itself With Alecensa Approval

Finance Watch: Canaan, Regeneron Reveal New Funds For Start-Ups

Investors Go Berserk For Viking, Putting It Top Of Q1 Winners

Sanofi Skates To Where The Puck Is With Immunology

See All
UsernamePublicRestriction

Register

SC071790

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By